PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16403819-12	2006	The insulin secretion measured in the supernatant was the same whether INS-1 cells were treated by dopamine or Lodosyn or untreated.	Carbidopa	111-118	insulin	Homo sapiens	4-11	
15258132-0	2004	Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle.	Carbidopa	14-23	insulin	Homo sapiens	91-98	
15258132-1	2004	We hypothesized that levodopa with carbidopa, a common therapy for patients with Parkinson"s disease, might contribute to the high prevalence of insulin resistance reported in patients with Parkinson"s disease.	Carbidopa	35-44	insulin	Homo sapiens	145-152	
15258132-5	2004	Levodopa-carbidopa also inhibited the insulin-stimulated increase in glycogen synthase activity, whereas propranolol attenuated this effect.	Carbidopa	9-18	insulin	Homo sapiens	38-45	
15258132-6	2004	Insulin-stimulated tyrosine phosphorylation of insulin receptor substrate (IRS)-1 was reduced by levodopa-carbidopa, although Akt phosphorylation was unaffected by levodopa-carbidopa.	Carbidopa	106-115	insulin	Homo sapiens	0-7	
15258132-6	2004	Insulin-stimulated tyrosine phosphorylation of insulin receptor substrate (IRS)-1 was reduced by levodopa-carbidopa, although Akt phosphorylation was unaffected by levodopa-carbidopa.	Carbidopa	173-182	insulin	Homo sapiens	0-7	
15258132-11	2004	The data demonstrate beta-adrenergic-dependent inhibition of insulin action by levodopa-carbidopa and suggest that unrecognized insulin resistance may exist in chronically treated patients with Parkinson"s disease.	Carbidopa	88-97	insulin	Homo sapiens	61-68